Noble Capital Markets Initiates Equity Research Coverage on Nutriband (NTRB)
Noble Capital Markets (Noble), a full-service SEC / FINRA-registered broker-dealer dedicated exclusively to serving public and private middle market companies and their investors, has initiated equity research coverage on Nutriband.
Noble’s Equity Research Analyst Robert LeBoyer launched coverage today with his report titled “Initiating Coverage With An Outperform Rating and $13 Price Target” The full report can be viewed, at no cost, on Channelchek.com.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Their lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
About Noble Capital Markets
Established in 1984, Noble Capital Markets is an SEC / FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform. We deliver middle market expertise to entrepreneurs, corporations, financial sponsors, and investors. Over the past 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports.
About Channelchek
Noble launched www.channelchek.com in 2018 – an investor community dedicated exclusively to public emerging growth companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 7,000 public emerging growth companies are listed on the site, and content including equity research, webcasts, and industry articles.